Breaking News: HSE’s spending on weight-loss injections tops €200m in under three years

The scale of public spending revealed in breaking news Ireland around weight-loss and diabetes injections is likely to intensify debate over healthcare budgets, access rules and long-term prescribing trends. New figures show the HSE spent more than €200 million on Ozempic and Saxenda in less than three years, with around 80,000 patients receiving the medicines through State-backed drug schemes in 2025.

Records released under freedom of information indicate that the health service spent an average of roughly €550,000 per day last year on the two injectable medicines. The data also points to a sharp rise in uptake since 2023, underlining how rapidly demand has grown across multiple regions.

HSE drug bill rises sharply in latest news Ireland

The figures cover the period from January 2023 to September 2025 and show total spending of just under €212 million on Ozempic and Saxenda through the medical card scheme, the Drugs Payment Scheme and the Long-Term Illness scheme.

Key takeaways include:

• More than €161.9 million was spent on Ozempic under the Long-Term Illness scheme.
• About 59,279 patients received Ozempic through that scheme during the first eight months of 2025.
• That represented a 34% increase compared with 2023.
• A further €41.2 million was spent on Ozempic and Saxenda for medical card patients over the same broader period.
• Under the Drugs Payment Scheme, spending reached €8.8 million.

For readers following Ireland health news and ireland current affairs, the numbers highlight the financial pressure that newer high-demand medicines can place on the public system.

Why Ozempic and Saxenda are treated differently

Although Ozempic is widely associated with weight loss, the HSE only funds it through free drug schemes for eligible patients diagnosed with diabetes, because it does not have marketing authorisation for weight management. Saxenda, by contrast, is specifically funded by the HSE for weight management under certain schemes, including the medical card and Drugs Payment Scheme.

This distinction matters in irish news today because it shapes who can access treatment at taxpayers’ expense and who must seek private prescriptions or pay privately.

Regional patterns raise fresh questions

The figures also reveal substantial regional differences in how often these medicines are dispensed. In total, 4,531 people in Kildare and West Wicklow received the injections last year through free drugs schemes, while 4,322 patients were recorded in North Dublin and 3,991 in Galway.

At the lower end, West Cork had 1,007 recipients, followed by Roscommon with 1,030 and Dun Laoghaire with 1,148.

Looking specifically at Ozempic under the Long-Term Illness scheme, Kildare and West Wicklow accounted for the highest spend at €9.7 million, with 3,418 patients receiving the drug there last year. North Dublin and Galway were next among the highest-use areas.

Medical card and DPS trends

Among medical card holders, 17,968 patients received Ozempic or Saxenda last year, an increase of 26% since 2023. Galway recorded the highest number of medical card recipients during the first eight months of 2025, with 1,019 patients, followed by Limerick with 955. Dun Laoghaire and West Cork had the lowest totals.

Meanwhile, 3,168 people were prescribed the medicines under the Drugs Payment Scheme during the first eight months of 2025.

What happens next for Ireland health news?

The HSE has said assessment processes are underway that will help determine whether other high-profile medications, including Mounjaro and Wegovy, could eventually be reimbursed under public drug schemes. That decision will be closely watched in ireland news today, especially as demand for GLP-1 medicines continues to rise internationally.

The broader debate is likely to focus on several issues:

1. How the State balances diabetes treatment with obesity care.
2. Whether reimbursement rules should expand as new evidence emerges.
3. How to manage spending growth without restricting necessary access.
4. Whether regional variation reflects demographics, prescribing practices or service access.

FAQs

How much did the HSE spend on these injections?

Just under €212 million was spent on Ozempic and Saxenda between January 2023 and September 2025 across several public drug schemes.

Who gets Ozempic funded by the HSE?

Under HSE rules, Ozempic is funded for eligible adults with diabetes rather than for weight management alone.

Is Saxenda funded for weight loss?

Yes. Saxenda is funded by the HSE for weight management through certain schemes, including the medical card and Drugs Payment Scheme.

Which areas had the highest use?

Kildare and West Wicklow, North Dublin and Galway were among the highest-use areas in the released figures.

This breaking news Ireland story shows just how quickly demand for GLP-1 medicines has grown within the public health system. The main takeaway from this breaking news Ireland update is clear: spending, access and future reimbursement decisions are now set to become an even bigger part of the national healthcare conversation.